Drug intelligence / Profile preview

FEP633 + FEP600

Development stage
Preclinical
Lead developer
PRISM BioLab
Modality
Small Molecules, Peptides
01

Overview

FEP633 and FEP600 are preclinical-stage small molecule peptide mimetics (PepMetics) developed by PRISM BioLab for the treatment of urothelial carcinoma. FEP600 functions as a mimetic of the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1), which competitively inhibits the protein-protein interaction (PPI) between eukaryotic translation initiation factor 4E (eIF4E) and eukaryotic translation initiation factor 4G1 (eIF4G1). By disrupting the formation of the eIF4F translation initiation complex, these compounds suppress the translation of oncogenic mRNAs involved in tumor growth and progression. FEP633 is a prodrug of FEP600, currently in the final stages of lead optimization. Preclinical studies in patient-derived xenograft (PDX) models of muscle-invasive and metastatic urothelial carcinoma have demonstrated that FEP600 possesses superior anti-tumor activity compared to standard-of-care cisplatin.

Other names
FEP633/FEP600
02

Targets

EIF4E (Eukaryotic translation initiation factor 4E)EIF4G1 (Eukaryotic translation initiation factor 4 gamma 1)

Beyond the preview

Go deeper on FEP633 + FEP600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on FEP633 + FEP600.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call